TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC) is a healthcare-focused blank-check company that completed its initial public offering in 2021, targeting opportunities in medical technology and life sciences. The SPAC filed a Form 10-Q on August 10, 2022, reflecting its financial position during the period ahead of its announced business combination with TriSalus Life Sciences, an oncology-focused medical device company developing pressure-enabled regional drug delivery systems designed to treat liver and pancreatic cancers. The transaction closed in September 2022, bringing TriSalus to public markets on Nasdaq under its own name. Sign up at SpacDesk for full data coverage on MTAC, including filing history, deal metrics, and transaction timelines.